Top

Published in:

01-02-2015 | Review Article

Neuromyelitis optica spectrum disorders associated with other autoimmune diseases

Authors: Eduardo Freitas, Joana Guimarães

Published in: Rheumatology International | Issue 2/2015

Abstract

Neuromyelitis optica (NMO) is an inflammatory demyelinating autoimmune disease with severe, tremendously incapacitating, consequences in the patient’s health and wellbeing. Until 2004, NMO was considered a restricted type of multiple sclerosis but in the same year an auto-antibody reacting against aquaporin-4 (NMO-IgG) was found to be related with NMO and it was considered the main etiologic agent of this disease. Its detection is very sensitive and specific allowing an early diagnosis and a better treatment and prognosis. With this tool, a spectrum of diseases including other autoimmune diseases was found to have NMO-IgG antibodies and a new classification named NMO spectrum disorders was created. In this review, we sum up the developments in this field associated with other autoimmune diseases. We approach the latest discoveries in the diagnosis like the new biomarkers that will possibly be used in the close future or the developments in the neuroimaging techniques. We reviewed the literature and synthesized case reports of NMO patients with concurrent autoimmune diseases and the information from useful larger studies. Finally, we summarize the commonly used treatments in NMO and we try to specify the best treatment for NMO with simultaneous autoimmune disease. This review updates the information about this issue and raises the awareness of rheumatologists for these severe diseases.

Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17(8):1019–1032. doi:10.1111/j.1468-1331.2010.03066.x PubMedCrossRef

Fazio R, Radaelli M, Furlan R (2011) Neuromyelitis optica: concepts in evolution. J Neuroimmunol 231(1–2):100–104. doi:10.1016/j.jneuroim.2010.10.012 PubMedCrossRef

Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364(9451):2106–2112. doi:10.1016/S0140-6736(04)17551-X PubMedCrossRef

Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202(4):473–477. doi:10.1084/jem.20050304 PubMedCentralPubMedCrossRef

Kim W, Kim SH, Huh SY, Kim HJ (2012) Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012:735486. doi:10.1155/2012/735486 PubMedCentralPubMed

Weinshenker BG, Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA (2006) NMO-IgG: a specific biomarker for neuromyelitis optica. Dis Markers 22(4):197–206PubMedCentralPubMedCrossRef

Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, Lucchinetti CF, Zephir H, Moder K, Weinshenker BG (2008) Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 65(1):78–83. doi:10.1001/archneurol.2007.17 PubMedCrossRef

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O’Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. doi:10.1002/ana.22366 PubMedCentralPubMedCrossRef

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815. doi:10.1016/S1474-4422(07)70216-8 PubMedCrossRef

10.

Matà S, Lolli F (2011) Neuromyelitis optica: an update. J Neurol Sci 303(1–2):13–21. doi:10.1016/j.jns.2011.01.002 PubMedCrossRef

11.

Bizzoco E, Lolli F, Repice AM, Hakiki B, Falcini M, Barilaro A, Taiuti R, Siracusa G, Amato MP, Biagioli T, Lori S, Moretti M, Vinattieri A, Nencini P, Massacesi L, Mata S (2009) Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J Neurol 256(11):1891–1898. doi:10.1007/s00415-009-5171-x PubMedCrossRef

12.

Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Kleiter I, Reindl M, Akman-Demir G, Seifert-Held T, Kristoferitsch W, Melms A, Wandinger KP, Wildemann B (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler (Houndmills, Basingstoke, England) 17(9):1067–1073. doi:10.1177/1352458511403958 CrossRef

13.

Kolfenbach JR, Horner BJ, Ferucci ED, West SG (2011) Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res 63(8):1203–1208. doi:10.1002/acr.20486 CrossRef

14.

Wingerchuk DM, Weinshenker BG (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler (Houndmills, Basingstoke, England) 18(1):5–10. doi:10.1177/1352458511431077 CrossRef

15.

McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, Chan KH, Weinshenker BG, Apiwattinakul M, Wingerchuk DM, Pittock SJ (2009) Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve 39(1):87–90. doi:10.1002/mus.21197 PubMedCrossRef

16.

Uzawa A, Mori M, Iwai Y, Kobayashi M, Hayakawa S, Kawaguchi N, Kuwabara S (2009) Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis. J Neurol Sci 287(1–2):105–107. doi:10.1016/j.jns.2009.08.040 PubMedCrossRef

17.

Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M, Ruprecht K, Liebetrau M, Wandinger KP, Akman-Demir G, Melms A, Kristoferitsch W, Wildemann B (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler (Houndmills, Basingstoke, England) 18(8):1135–1143. doi:10.1177/1352458511431728 CrossRef

18.

Leite MI, Coutinho E, Lana-Peixoto M, Apostolos S, Waters P, Sato D, Melamud L, Marta M, Graham A, Spillane J, Villa AM, Callegaro D, Santos E, da Silva AM, Jarius S, Howard R, Nakashima I, Giovannoni G, Buckley C, Hilton-Jones D, Vincent A, Palace J (2012) Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78(20):1601–1607. doi:10.1212/WNL.0b013e31825644ff PubMedCentralPubMedCrossRef

19.

Kay CS, Scola RH, Lorenzoni PJ, Jarius S, Arruda WO, Werneck LC (2008) NMO-IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 275(1–2):148–150. doi:10.1016/j.jns.2008.06.038 PubMedCrossRef

20.

Chan KH, Kwan JS, Ho PW, Ho SL, Chui WH, Chu AC, Ho JW, Zhang WY, Kung MH (2010) Aquaporin-4 water channel expression by thymoma of patients with and without myasthenia gravis. J Neuroimmunol 227(1–2):178–184. doi:10.1016/j.jneuroim.2010.07.016 PubMedCrossRef

21.

Klein R, Marx A, Ströbel P, Schalke B, Nix W, Willcox N (2013) Autoimmune associations and autoantibody screening show focused recognition in patient subgroups with generalized myasthenia gravis. Hum Immunol 74(9):1184–1193. doi:10.1016/j.humimm.2013.06.020 PubMedCrossRef

22.

Vincent A, Waters P, Leite MI, Jacobson L, Koneczny I, Cossins J, Beeson D (2012) Antibodies identified by cell-based assays in myasthenia gravis and associated diseases. Ann N Y Acad Sci 1274:92–98. doi:10.1111/j.1749-6632.2012.06789.x PubMedCrossRef

23.

Javed A, Balabanov R, Arnason BG, Kelly TJ, Sweiss NJ, Pytel P, Walsh R, Blair EA, Stemer A, Lazzaro M, Reder AT (2008) Minor salivary gland inflammation in Devic’s disease and longitudinally extensive myelitis. Mult Scler (Houndmills, Basingstoke, England) 14(6):809–814. doi:10.1177/1352458508088941 CrossRef

24.

Kim SM, Waters P, Vincent A, Kim SY, Kim HJ, Hong YH, Park KS, Min JH, Sung JJ, Lee KW (2009) Sjogren’s syndrome myelopathy: spinal cord involvement in Sjogren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler (Houndmills, Basingstoke, England) 15(9):1062–1068. doi:10.1177/1352458509106636 CrossRef

25.

Min JH, Kim HJ, Kim BJ, Lee KW, Sunwoo IN, Kim SM, Kim BJ, Kim SH, Park MS, Waters P, Vincent A, Sung JJ, Lee KH (2009) Brain abnormalities in Sjogren syndrome with recurrent CNS manifestations: association with neuromyelitis optica. Mult Scler (Houndmills, Basingstoke, England) 15(9):1069–1076. doi:10.1177/1352458509106228 CrossRef

26.

Gokcay F, Celebisoy N, Gokcay A, Kabasakal Y, Oder G (2007) Primary Sjogrens syndrome presenting as neuromyelitis optica. Pediatr Neurol 36(1):58–60. doi:10.1016/j.pediatrneurol.2006.07.008 PubMedCrossRef

27.

Kahlenberg JM (2011) Neuromyelitis optica spectrum disorder as an initial presentation of primary Sjogren’s syndrome. Semin Arthritis Rheum 40(4):343–348. doi:10.1016/j.semarthrit.2010.05.005 PubMedCrossRef

28.

Tan P, Yu WY, Umapathi T, Lim SA (2012) Severe optic neuritis in a patient with combined neuromyelitis optica spectrum disease and primary Sjogren’s syndrome: a case report. J Med Case Rep 6(1):401. doi:10.1186/1752-1947-6-401 PubMedCentralPubMedCrossRef

29.

Min JH, Kim SH, Park MS, Kim BJ, Lee KH (2010) Brain MRI lesions characteristic of neuromyelitis optica and positive anti-aquaporin 4-antibody may predict longitudinal extensive myelitis and optic neuritis in Sjogren’s syndrome. Mult Scler (Houndmills, Basingstoke, England) 16(6):762–764. doi:10.1177/1352458510361740 CrossRef

30.

Koga S, Ikeda K, Nakagomi D, Mori M, Kuwabara S, Nakajima H (2011) A patient with neuromyelitis optica with positive anti-Ro (SS-A) antibody presenting with intractable hiccup and nausea. Mod Rheumatol/Jpn Rheum Assoc 21(5):561–562. doi:10.1007/s10165-011-0438-3 CrossRef

31.

Katsumata Y, Kawachi I, Kawaguchi Y, Gono T, Ichida H, Hara M, Yamanaka H (2012) Semiquantitative measurement of aquaporin-4 antibodies as a possible surrogate marker of neuromyelitis optica spectrum disorders with systemic autoimmune diseases. Mod Rheumatol/Jpn Rheum Assoc 22(5):676–684. doi:10.1007/s10165-011-0572-y CrossRef

32.

Birnbaum J, Kerr D (2008) Optic neuritis and recurrent myelitis in a woman with systemic lupus erythematosus. Nat Clin Pract Rheumatol 4(7):381–386. doi:10.1038/ncprheum0818 PubMed

33.

Mehta LR, Samuelsson MK, Kleiner AK, Goodman AD, Anolik JH, Looney RJ, Schwid SR (2008) Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mult Scler (Houndmills, Basingstoke, England) 14(3):425–427. doi:10.1177/1352458507084107 CrossRef

34.

Polgár A, Rózsa C, Müller V, Matolcsi J, Poór G, Kiss EV (2011) Devic’s syndrome and SLE: challenges in diagnosis and therapeutic possibilities based on two overlapping cases. Autoimmun Rev 10(3):171–174. doi:10.1016/j.autrev.2010.09.021 PubMedCrossRef

35.

Arul Selvan VL (2013) A case of neuromyelitis optica as a presenting manifestation of systemic lupus erythematosus. Apollo Med 10(3):226–229. doi:10.1016/j.apme.2013.08.005 CrossRef

36.

Mottaghi P, Ashtari F, Karimzadeh H, Seidbonakdar Z, Karimifar M, Salesi M (2009) Devic’s syndrome concomitant with nephritis in a young woman. Clin Rheumatol 28(10):1239–1240. doi:10.1007/s10067-009-1232-x PubMedCrossRef

37.

Franciotta D, Zardini E, Caporali R, Piccolo L, Alberici E, Romani A, Bergamaschi R, Marchioni E, Ceroni M, Piccolo G (2011) Systemic sclerosis in aquaporin-4 antibody-positive longitudinally extensive transverse myelitis. J Neurol Sci 303(1–2):139–141. doi:10.1016/j.jns.2011.01.011 PubMedCrossRef

38.

Sawaya R, Radwan W (2013) Sarcoidosis associated with neuromyelitis optica. J Clin Neurosc 20(8):1156–1158. doi:10.1016/j.jocn.2012.09.030 CrossRef

39.

Jacob A, McKeon A, Nakashima I, Sato DK, Elsone L, Fujihara K, de Seze J (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84(8):922–930. doi:10.1136/jnnp-2012-302310 PubMedCrossRef

40.

González C, González-Buitrago JM, Izquierdo G (2013) Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. Clin Chim Acta 415(0):350–360. doi:10.1016/j.cca.2012.04.027 PubMedCrossRef

41.

Misu T, Hoftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima I, Konno H, Bradl M, Garzuly F, Itoyama Y, Aoki M, Lassmann H (2013) Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica. Acta Neuropathol 125(6):815–827. doi:10.1007/s00401-013-1116-7 PubMedCentralPubMedCrossRef

42.

Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, Antel JP (2008) Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood–brain barrier permeability and granulocyte recruitment. J Immunol (Baltimore, Md : 1950) 181(8):5730–5737CrossRef

43.

Waters P, Vincent A (2008) Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J/MS Forum 15(3):99–105

44.

Kalluri SR, Illes Z, Srivastava R, Cree B, Menge T, Bennett JL, Berthele A, Hemmer B (2010) Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 67(10):1201–1208. doi:10.1001/archneurol.2010.269 PubMedCrossRef

45.

Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, Palace J, Mandrekar JN, Vincent A, Bar-Or A, Pittock SJ (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671. doi:10.1212/WNL.0b013e318248dec1 (discussion 669)PubMedCentralPubMedCrossRef

46.

Oh J, Levy M (2012) Neuromyelitis optica: an antibody-mediated disorder of the central nervous system. Neurol Res Int 2012:460825. doi:10.1155/2012/460825 PubMedCentralPubMedCrossRef

47.

Dellavance A, Alvarenga RR, Rodrigues SH, Kok F, de Souza AWS, Andrade LEC (2012) Anti-aquaporin-4 antibodies in the context of assorted immune-mediated diseases. Eur J Neurol 19(2):248–252. doi:10.1111/j.1468-1331.2011.03479.x PubMedCrossRef

48.

Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B (2011) Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 306(1–2):82–90. doi:10.1016/j.jns.2011.03.038 PubMedCrossRef

49.

Jarius S, Franciotta D, Paul F, Ruprecht K, Bergamaschi R, Rommer PS, Reuss R, Probst C, Kristoferitsch W, Wandinger KP, Wildemann B (2010) Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance. J Neuroinflammation 7:52. doi:10.1186/1742-2094-7-52 PubMedCentralPubMedCrossRef

50.

Long Y, Qiu W, Lu Z, Bao J, Wu A, Wang Y, Wang H, Hu X (2012) Aquaporin 4 antibodies in the cerebrospinal fluid are helpful in diagnosing Chinese patients with neuromyelitis optica. Neuroimmunomodulation 19(2):96–102. doi:10.1159/000330240 PubMedCrossRef

51.

Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, Lutterotti A, Jarius S, Di Pauli F, Kuenz B, Ehling R, Hegen H, Deisenhammer F, Aboul-Enein F, Storch MK, Koson P, Drulovic J, Kristoferitsch W, Berger T, Reindl M (2011) Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 8:184. doi:10.1186/1742-2094-8-184 PubMedCentralPubMedCrossRef

52.

Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, Ito S, Nomura F, Kuwabara S (2013) Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks. Clin Chim Acta 421:181–183. doi:10.1016/j.cca.2013.03.020 PubMedCrossRef

53.

Storoni M, Petzold A, Plant GT (2011) The use of serum glial fibrillary acidic protein measurements in the diagnosis of neuromyelitis optica spectrum optic neuritis. PLoS One 6(8):e23489. doi:10.1371/journal.pone.0023489 PubMedCentralPubMedCrossRef

54.

Wang KC, Tsai CP, Lee CL, Chen SY, Chin LT, Chen SJ (2012) Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226:510–516. doi:10.1016/j.neuroscience.2012.08.041 PubMedCrossRef

55.

Tzartos JS, Stergiou C, Kilidireas K, Zisimopoulou P, Thomaidis T, Tzartos SJ (2013) Anti-aquaporin-1 autoantibodies in patients with neuromyelitis optica spectrum disorders. PLoS One 8(9):e74773. doi:10.1371/journal.pone.0074773 PubMedCentralPubMedCrossRef

56.

Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH (2008) Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (Houndmills, Basingstoke, England) 14(9):1157–1174. doi:10.1177/1352458508096878 CrossRef

57.

Kim W, Kim SH, Lee SH, Li XF, Kim HJ (2011) Brain abnormalities as an initial manifestation of neuromyelitis optica spectrum disorder. Mult Scler (Houndmills, Basingstoke, England) 17(9):1107–1112. doi:10.1177/1352458511404917 CrossRef

58.

Min JH, Waters P, Vincent A, Kang ES, Lee S, Lee DK, Lee KH, Kim BJ (2013) Symptomatic brain involvement as the initial manifestation of neuromyelitis optica. J Clin Neurosc 20(7):938–942. doi:10.1016/j.jocn.2012.08.007 CrossRef

59.

Kuker W (2007) Imaging of cerebral vasculitis. Int J Stroke 2(3):184–190. doi:10.1111/j.1747-4949.2007.00134.x PubMedCrossRef

60.

Eckstein C, Saidha S, Levy M (2012) A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis. J Neurol 259(5):801–816. doi:10.1007/s00415-011-6240-5 PubMedCrossRef

61.

Kimbrough DJ, Fujihara K, Jacob A, Lana-Peixoto MA, Isabel Leite M, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1(4):180–187. doi:10.1016/j.msard.2012.06.002 PubMedCentralPubMedCrossRef

62.

Bonnan M, Valentino R, Olindo S, Mehdaoui H, Smadja D, Cabre P (2009) Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult Scler (Houndmills, Basingstoke, England) 15(4):487–492. doi:10.1177/1352458508100837 CrossRef

63.

Lim YM, Pyun SY, Kang BH, Kim J, Kim KK (2013) Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders. Mult Scler (Houndmills, Basingstoke, England) 19(9):1216–1218. doi:10.1177/1352458512471875 CrossRef

64.

Yaguchi H, Sakushima K, Takahashi I, Nishimura H, Yashima-Yamada M, Nakamura M, Tsuzaka K, Maruo Y, Takahashi T, Yabe I, Sasaki H (2013) Efficacy of intravenous cyclophosphamide therapy for neuromyelitis optica spectrum disorder. Intern Med (Tokyo, Japan) 52(9):969–972CrossRef

65.

Jacob A, Matiello M, Weinshenker BG et al (2009) Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66(9):1128–1133. doi:10.1001/archneurol.2009.175 PubMedCrossRef

66.

Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 84(8):918–921. doi:10.1136/jnnp-2012-304774 PubMedCrossRef

67.

Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler (Houndmills, Basingstoke, England) 17(10):1225–1230. doi:10.1177/1352458511404586 CrossRef

68.

Ip VH, Lau AY, Au LW, Fan FS, Chan AY, Mok VC, Wong KS (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324(1–2):38–39. doi:10.1016/j.jns.2012.09.024 PubMedCrossRef

69.

Danes I, Agusti A, Vallano A, Martinez J, Alerany C, Ferrer A, Lopez A, Cortes-Hernandez J, Bosch JA (2013) Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol 69(9):1689–1699. doi:10.1007/s00228-013-1518-4 PubMedCrossRef

70.

Pittock SJ, Lennon VA, McKeon A, Mandrekar J, Weinshenker BG, Lucchinetti CF, O’Toole O, Wingerchuk DM (2013) Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study. Lancet Neurol 12(6):554–562. doi:10.1016/s1474-4422(13)70076-0 PubMedCrossRef

71.

Gurcan HM, Keskin DB, Stern JN, Nitzberg MA, Shekhani H, Ahmed AR (2009) A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol 9(1):10–25. doi:10.1016/j.intimp.2008.10.004 PubMedCrossRef

72.

Kim SH, Kim W, Huh SY, Lee KY, Jung IJ, Kim HJ (2013) Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels. J Clin Neurol (Seoul, Korea) 9(1):36–42. doi:10.3988/jcn.2013.9.1.36 CrossRef

73.

Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A (2013) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler. doi:10.1177/1352458513495938

74.

Guimarães J, Sá M (2007) Devic disease with abnormal brain magnetic resonance image findings: the first portuguese case. Arch Neurol 64(2):290–291. doi:10.1001/archneur.64.2.290

Title: Neuromyelitis optica spectrum disorders associated with other autoimmune diseases
Authors: Eduardo Freitas
Joana Guimarães
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 2/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-014-3066-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Neuromyelitis optica spectrum disorders associated with other autoimmune diseases

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Hypovitaminosis D in widespread pain: its effect on pain perception, quality of life and nerve conduction studies

Etanercept biosimilars

Chronic inflammatory arthritis prevalence estimates for children and adolescents in three Canadian provinces

Pneumococcal arthroentesitis and multiple myeloma

Ayurvedic interventions for osteoarthritis: a systematic review and meta-analysis

Spinal cord infarction in giant cell arteritis associated with scalp necrosis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page